|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPL42 |
Gene summary for MRPL42 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPL42 | Gene ID | 28977 |
| Gene name | mitochondrial ribosomal protein L42 | |
| Gene Alias | HSPC204 | |
| Cytomap | 12q22 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | A0A024RBG3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 28977 | MRPL42 | ATC5 | Human | Thyroid | ATC | 8.48e-23 | 3.02e-01 | 0.34 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPL42 | SNV | Missense_Mutation | novel | c.176N>C | p.Val59Ala | p.V59A | Q9Y6G3 | protein_coding | deleterious(0.04) | possibly_damaging(0.855) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| MRPL42 | SNV | Missense_Mutation | novel | c.164N>A | p.Gly55Asp | p.G55D | Q9Y6G3 | protein_coding | deleterious(0.04) | benign(0.138) | TCGA-AP-A1DH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPL42 | SNV | Missense_Mutation | c.4N>A | p.Ala2Thr | p.A2T | Q9Y6G3 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.828) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MRPL42 | SNV | Missense_Mutation | c.158N>G | p.Ser53Cys | p.S53C | Q9Y6G3 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-D1-A16S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| MRPL42 | SNV | Missense_Mutation | novel | c.26N>C | p.Val9Ala | p.V9A | Q9Y6G3 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| MRPL42 | SNV | Missense_Mutation | rs375756118 | c.230G>A | p.Arg77Gln | p.R77Q | Q9Y6G3 | protein_coding | tolerated(0.49) | benign(0.046) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPL42 | SNV | Missense_Mutation | novel | c.31N>C | p.Ser11Pro | p.S11P | Q9Y6G3 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.638) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| MRPL42 | SNV | Missense_Mutation | c.30N>T | p.Met10Ile | p.M10I | Q9Y6G3 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-53-7624-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
| MRPL42 | SNV | Missense_Mutation | novel | c.107N>T | p.Tyr36Phe | p.Y36F | Q9Y6G3 | protein_coding | tolerated(0.09) | benign(0.203) | TCGA-91-6836-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPL42 | SNV | Missense_Mutation | novel | c.269A>T | p.Gln90Leu | p.Q90L | Q9Y6G3 | protein_coding | tolerated(0.15) | benign(0.009) | TCGA-NJ-A4YF-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |